Cargando…
Ajmaline blocks I(Na) and I(Kr) without eliciting differences between Brugada syndrome patient and control human pluripotent stem cell-derived cardiac clusters
The class Ia anti-arrhythmic drug ajmaline is used clinically to unmask latent type I ECG in Brugada syndrome (BrS) patients, although its mode of action is poorly characterised. Our aims were to identify ajmaline's mode of action in human induced pluripotent stem cell (hiPSC)-derived cardiomyo...
Autores principales: | Miller, Duncan C., Harmer, Stephen C., Poliandri, Ariel, Nobles, Muriel, Edwards, Elizabeth C., Ware, James S., Sharp, Tyson V., McKay, Tristan R., Dunkel, Leo, Lambiase, Pier D., Tinker, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727153/ https://www.ncbi.nlm.nih.gov/pubmed/29172153 http://dx.doi.org/10.1016/j.scr.2017.11.003 |
Ejemplares similares
-
The challenges of performing ajmaline challenge in children with suspected Brugada syndrome
por: Conte, Giulio, et al.
Publicado: (2014) -
Proarrhythmogenic effects of lamotrigine during ajmaline testing for Brugada syndrome
por: Leong, Kevin M.W., et al.
Publicado: (2017) -
The Mechanism of Ajmaline and Thus Brugada Syndrome: Not Only the Sodium Channel!
por: Monasky, Michelle M., et al.
Publicado: (2021) -
Ajmaline‐Induced Abnormalities in Brugada Syndrome: Evaluation With ECG Imaging
por: Pannone, Luigi, et al.
Publicado: (2022) -
Ajmaline-induced Brugada Phenocopy, Right Bundle Branch Block, or Both?
por: Kafes, Habibe, et al.
Publicado: (2021)